New insider activity at NeoGenomics ( (NEO) ) has taken place on May 9, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CEO Anthony Zook has made a significant investment in NeoGenomics by purchasing 18,900 shares of the company’s stock, valued at $148,743.
Recent Updates on NEO stock
In the last 24 hours, NeoGenomics has seen several analysts lower their price targets due to recent financial performance and market conditions. Piper Sandler, Morgan Stanley, TD Cowen, BofA, and BTIG all reduced their targets, citing factors such as a Q1 earnings miss, lower non-clinical revenue, and a cautious outlook on the pharmaceutical environment. Analysts noted the company’s lower-than-expected average unit price and Pathline contribution, alongside an aggressive 2025 guidance despite sales misses in previous quarters. These developments have led to a significant selloff in NeoGenomics’ stock, reflecting concerns over its growth consistency and forward guidance potential.
Spark’s Take on NEO Stock
According to Spark, TipRanks’ AI Analyst, NEO is a Neutral.
NeoGenomics presents a mixed investment outlook. The company shows strong revenue growth and strategic initiatives, but faces challenges with profitability, high leverage, and negative cash flow. Technical indicators suggest bearish momentum, while the valuation metrics highlight ongoing losses. Corporate leadership changes and strategic acquisitions provide some positive momentum, but investors should be cautious due to the current financial and market conditions.
To see Spark’s full report on NEO stock, click here.
More about NeoGenomics
YTD Price Performance: -51.49%
Average Trading Volume: 2,072,656
Technical Sentiment Signal: Sell
Current Market Cap: $989.7M